Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaoru Tsuchiya

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
Scientific Reports|July 14, 2019
Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver diseaseNobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
Oncology|January 10, 2014
Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching studyYutaka Yasui, Atsushi Kudo, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 18, 2024
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver diseaseKeito Suzuki, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 8, 2013
Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patientsNobuharu Tamaki, Masayuki Kurosaki, Shuya Matsuda, et al.
Plos One|February 23, 2022
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapyKenta Takaura, Masayuki Kurosaki, Kento Inada, et al.
Journal of Viral Hepatitis|April 12, 2019
Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antiviralsNobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
BMC Gastroenterology|June 17, 2023
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver diseaseShun Ishido, Nobuharu Tamaki, Yuka Takahashi, et al.
Journal of Gastroenterology and Hepatology|June 21, 2021
Liver fibrosis and fatty liver as independent risk factors for cardiovascular diseaseNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
Cancer|October 15, 2013
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinomaKaoru Tsuchiya, Yasuhiro Asahina, Shuya Matsuda, et al.
Journal of Gastroenterology and Hepatology|April 25, 2019
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarateShun Kaneko, Masayuki Kurosaki, Nobuharu Tamaki, et al.
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
Scientific Reports|July 14, 2019
Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver diseaseNobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
Oncology|January 10, 2014
Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching studyYutaka Yasui, Atsushi Kudo, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 18, 2024
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver diseaseKeito Suzuki, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 8, 2013
Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patientsNobuharu Tamaki, Masayuki Kurosaki, Shuya Matsuda, et al.
Plos One|February 23, 2022
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapyKenta Takaura, Masayuki Kurosaki, Kento Inada, et al.
Journal of Viral Hepatitis|April 12, 2019
Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antiviralsNobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
BMC Gastroenterology|June 17, 2023
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver diseaseShun Ishido, Nobuharu Tamaki, Yuka Takahashi, et al.
Journal of Gastroenterology and Hepatology|June 21, 2021
Liver fibrosis and fatty liver as independent risk factors for cardiovascular diseaseNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
Cancer|October 15, 2013
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinomaKaoru Tsuchiya, Yasuhiro Asahina, Shuya Matsuda, et al.
Journal of Gastroenterology and Hepatology|April 25, 2019
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarateShun Kaneko, Masayuki Kurosaki, Nobuharu Tamaki, et al.
Pageof 15